NEW YORK, January 25, 2017 /PRNewswire/ --
Stock-Callers.com brings focus back on the Biotechnology industry to see how some equities have fared over the last few
trading sessions. Under evaluation this morning are: PharmAthene Inc. (NYSE MKT: PIP), Corcept Therapeutics Inc. (NASDAQ: CORT),
Navidea Biopharmaceuticals Inc (NYSE MKT: NAVB), and Inotek Pharmaceuticals Corp. (NASDAQ: ITEK). These companies belong to the
Healthcare sector which was the lone industry sector in the S&P 500 declining on Tuesday, January
24th, 2017. As per a NASDAQ report, the NYSE Health Care Index dropped 0.7%, while shares of health care
companies in the S&P 500 were down over 0.6% as a group. These stocks research reports can be downloaded now by simply
registering for free at: http://stock-callers.com/registration
PharmAthene
On Tuesday, shares in Annapolis, Maryland headquartered PharmAthene Inc. recorded a trading
volume of 1.74 million shares, which was above their three months average volume of 976,340 shares. The stock ended the session
flat at $3.35. The Company's shares have gained 3.08% in the last one month, 19.64% in the previous
three months, and 3.08% on an YTD basis. The stock is trading 5.21% above its 50-day moving average and 24.61% above its 200-day
moving average. Moreover, shares of PharmAthene, which develops and commercializes medical counter measures against biological
and chemical threats in the US, have a Relative Strength Index (RSI) of 54.89.
On January 19th, 2017, PharmAthene and Altimmune, Inc. announced the signing of a
definitive agreement for the merger of PharmAthene and Altimmune in an all-stock transaction. The combined Company will be a
fully-integrated and diversified immunotherapeutics Company with four clinical stage and one preclinical stage programs.
PharmAthene will issue shares of common stock to Altimmune's shareholders such that Altimmune's equity holders will own 58.2% of
the fully-diluted equity of the combined Company. The combined Company, which will operate as a public Company under the name
Altimmune, is expected to trade on the NYSE MKT under the ticker symbol ALT. The proposed transaction does not affect
PharmAthene's previously announced special one-time cash dividend of $2.91 per share of common
stock. Your complete research report on PIP can be retrieved for free at:
http://stock-callers.com/registration/?symbol=PIP
Corcept Therapeutics
Menlo Park, California headquartered Corcept Therapeutics Inc.'s stock closed the day 0.41%
higher at $7.27 with a total trading volume of 558,066 shares. The Company's shares have advanced
4.76% in the previous three months and 0.14% since the start of this year. The stock is trading 13.25% above its 200-day moving
average. Additionally, shares of Corcept Therapeutics, which engages in the discovery, development, and commercialization of
drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the US, have an RSI of 34.54.
On January 23rd, 2017, Corcept Therapeutics announced that it will report preliminary
Q4 2016 and 2016 financial results and provide 2017 revenue guidance and a corporate update on January
30th, 2017. The Company will also host a conference call that day at 5:00 p.m.
ET. A free report on CORT is just a click away at:
http://stock-callers.com/registration/?symbol=CORT
Navidea Biopharma
Shares in Dublin, Ohio headquartered Navidea Biopharmaceuticals Inc recorded a trading volume
of 510,308 shares, and ended yesterday's trading session 1.71% lower at $0.58. The stock is trading
below its 50-day moving average by 18.05%. Shares of the Company, which focuses on the development and commercialization of
precision immunodiagnostic agents and immunotherapeutics, have an RSI of 36.51. Sign up for your complimentary research report on
NAVB at:
http://stock-callers.com/registration/?symbol=NAVB
Inotek Pharma
Lexington, Massachusetts headquartered Inotek Pharmaceuticals Corp.'s stock finished
Tuesday's session flat at $1.52 with a total trading volume of 602,826 shares. The Company's are
trading below their 50-day moving average by 71.12%. Shares of the Company, which focuses on the discovery, development, and
commercialization of therapies for glaucoma and other diseases of the eye in the US, have an RSI of 19.38.
On January 03rd, 2017, Inotek Pharmaceuticals announced top-line results of MATrX-1,
the first pivotal Phase-3 trial of trabodenoson for the treatment of primary open-angle glaucoma or ocular hypertension.
The trial did not achieve its primary endpoint of superiority in reduction of intraocular pressure compared with placebo at all
12 time points. This was, in part, due to a placebo response that was 2-3 mmHg greater than that observed in Phase-2.
Trabodenoson, the Company's lead clinical candidate, is a first-in-class, highly selective adenosine mimetic targeting the
A1 subreceptor.
On January 04th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on
the Company's stock with a decrease of the target price from $22 a share to $7 a share. Register for free on Stock-Callers.com and download the latest research report on ITEK at:
http://stock-callers.com/registration/?symbol=ITEK
Stock Callers:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment
newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments.
One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports
covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered
analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and
micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a
third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on
analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document
templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is
believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed
any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently
reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or
interfere in the application of such procedures by the third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or
the Reviewer in any way.
NO WARRANTY
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document.
Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing
of the information, or (2) warrant any results from use of the information. The included information is subject to change without
notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities
mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers
in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with
any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://stock-callers.com/legal-disclaimer/
CONTACT
For any questions, inquiries, or comments reach out to us directly. If you're a
company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@stock-callers.com
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA